Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTHOTCMKTS:HCYTDOTCMKTS:LENSFOTCMKTS:VRSEF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$6K4.024,068 shs1,800 shsHCYTDH-CYTE$2.02-49.5%$2.02$2.02▼$77.00$521K1.12103 shs400 shsLENSFPresbia$0.02$0.02$0.00▼$0.19$257K5.915,650 shsN/AVRSEFVerisante Technology$0.00$0.00$0.00▼$0.01$100K18.297 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%+33.33%-99.38%-99.88%HCYTDH-CYTE0.00%0.00%0.00%0.00%0.00%LENSFPresbia0.00%0.00%0.00%0.00%0.00%VRSEFVerisante Technology0.00%0.00%+4.76%-56.00%-4.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHCYTDH-CYTEN/AN/AN/AN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/AN/AN/AN/AVRSEFVerisante TechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AHCYTDH-CYTE 0.00N/AN/AN/ALENSFPresbia 0.00N/AN/AN/AVRSEFVerisante Technology 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00HCYTDH-CYTE$1.61M0.32N/AN/A($31.45) per share-0.06LENSFPresbiaN/AN/AN/AN/AN/AN/AVRSEFVerisante TechnologyN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)HCYTDH-CYTE-$4.80MN/A0.00∞N/A-450.40%N/A-777.68%N/ALENSFPresbiaN/AN/A0.00∞N/AN/AN/AN/AN/AVRSEFVerisante Technology-$80KN/A0.00∞N/AN/AN/A-901.36%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AHCYTDH-CYTEN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/AVRSEFVerisante TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01HCYTDH-CYTEN/A0.120.12LENSFPresbiaN/AN/AN/AVRSEFVerisante TechnologyN/A0.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%HCYTDH-CYTEN/ALENSFPresbiaN/AVRSEFVerisante TechnologyN/AInsider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%HCYTDH-CYTE5.24%LENSFPresbia74.20%VRSEFVerisante TechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableHCYTDH-CYTE8258,000244,000Not OptionableLENSFPresbia2017.12 millionN/ANot OptionableVRSEFVerisante TechnologyN/A43.94 millionN/ANot OptionableVRSEF, ARTH, HCYTD, and LENSF HeadlinesRecent News About These CompaniesVER.H:CA AnalysisApril 10, 2025 | seekingalpha.comVerisante Technology, Inc. Announces Termination of Proposed RTO with SunRegen Healthcare AGMarch 31, 2025 | accessnewswire.comAVerisante Technology, Inc. Announces RTO Update:December 18, 2024 | accesswire.comAVerisante Technology, Inc. Announces Update to Proposed RTO with SunRegen Healthcare AGOctober 31, 2024 | accesswire.comAVerisante Technology, Inc. Announces Proposed RTO with SunRegen Healthcare AGAugust 13, 2024 | accesswire.comAClosing Bell: Verisante Technology Inc down on Friday (VER-H)August 7, 2024 | theglobeandmail.comClosing Bell: Verisante Technology Inc up on Tuesday (VER-H)July 24, 2024 | theglobeandmail.comVerisante Technology, Inc. Announces Exchange Acceptance of Shares for Debt TransactionMarch 30, 2024 | accesswire.comAVerisante: Q4 Earnings SnapshotMarch 29, 2024 | sfgate.comVerisante Technology, Inc. Announces Shares for Debt AgreementsMarch 14, 2024 | accesswire.comAVerisante Technology, Inc. Announces 2023 AGM ResultsDecember 21, 2023 | finance.yahoo.comVerisante Technology, Inc. Announces Exchange Approval for Shares for Debt TransactionOctober 5, 2023 | finance.yahoo.comVerisante Technology Inc. Announces Shares for Debt AgreementsSeptember 8, 2023 | finance.yahoo.comVerisante: Q2 Earnings SnapshotAugust 15, 2023 | wtop.comWLatest Technology NewsMarch 30, 2023 | prweek.comPVerisante Technology, Inc. Announces Exchange Acceptance for Shares for Debt TransactionsNovember 23, 2022 | finance.yahoo.comVerisante: Q3 Earnings SnapshotNovember 18, 2022 | sfgate.comVerisante Technology, Inc.: Verisante Technology Inc. Announces Proposed Shares for Debt TransactionOctober 22, 2022 | finanznachrichten.deVerisante Technology Inc. Announces Proposed Shares for Debt TransactionOctober 19, 2022 | finance.yahoo.comVerisante Technology Inc. Announces Closing Non-Brokered Private PlacementJuly 13, 2022 | apnews.comAMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeApple’s Quiet HomePad Delay Could Be Its Loudest Move YetBy Chris Markoch | June 1, 2025View Apple’s Quiet HomePad Delay Could Be Its Loudest Move YetVRSEF, ARTH, HCYTD, and LENSF Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.H-CYTE OTCMKTS:HCYTD$2.02 -1.98 (-49.50%) As of 07/11/2022H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Presbia OTCMKTS:LENSF$0.02 0.00 (0.00%) As of 10/21/2022Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.Verisante Technology OTCMKTS:VRSEF$0.0022 0.00 (0.00%) As of 06/20/2025Verisante Technology Inc. does not have significant operations. Previously, it was involved in the design and manufacture of cancer diagnostic devices. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. The company was incorporated in 2006 and is based in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
